Developer docs
API playgroundTry for free, no card

Search company profiles

NicOx

Full company profile

uuid0002i6d

Namestring
NicOx
Legal namestring
Nicox SA
Websiteurl
nicox.com
Company typeenum
Public
Founded yearint
1996
Descriptiontext

Nicox is an international ophthalmology company headquartered in Biot (Sophia Antipolis), France, developing nitric oxide (NO)-donating therapeutics to treat ocular diseases. Founded in 1996 and listed on Euronext Growth Paris under ticker ALCOX, the company employs 11-50 people and operates a wholly-owned US R&D subsidiary, Nicox Ophthalmics, Inc., in Durham, NC, focused on chemistry, manufacturing and controls and clinical development. The proprietary NO-donation platform enables novel dual-mechanism ophthalmic drugs; the lead candidate NCX 470 (NO-donating bimatoprost) demonstrated up to 10mmHg intraocular pressure reduction in Phase 3 trials with non-inferiority to latanoprost at all time points and statistical superiority at 3 of 6 time points, and is positioned for NDA submissions in the US and China in summer 2026.

The portfolio spans commercial and development assets. VYZULTA (latanoprostene bunod) is commercialized globally by partner Bausch + Lomb; ZERVIATE (cetirizine ophthalmic solution) is commercialized in the US by Eyevance and in China by Ocumension (first sale December 2024); pipeline candidates include NCX 4251 for blepharitis/dry eye, NCX 1728 (optioned to Glaukos for a new class of NO-mediated IOP-lowering agents), and naproxcinod (licensed to Fera Pharmaceuticals with FDA orphan drug designation for sickle cell disease).

Nicox operates an asset-light, partner-driven business model with no proprietary commercial infrastructure. It licenses drug candidates to regional pharmaceutical companies (Kowa for US/Japan NCX 470 under a deal worth up to €191.5M, Ocumension for China, Bausch + Lomb for VYZULTA, Eyevance for US ZERVIATE, Laboratorios Grin for Mexico, Glaukos for NCX 1728, Fera for naproxcinod), generating revenue through upfront payments, regulatory and commercial milestone payments, and royalties on partner-led sales. FY2025 revenue more than doubled to €16.8 million from €7.9 million in 2024, driven primarily by Kowa milestones; net loss narrowed sharply to €2.4 million from €22.4 million; all secured debt to Kreos Capital was fully repaid by December 31, 2025; and cash runway extends beyond 2027.

Short descriptiontext

Nicox is a France-based ophthalmology company developing nitric oxide-donating therapeutics for glaucoma and ocular diseases. It licenses its pipeline—including lead asset NCX 470—to regional pharmaceutical partners across the US, China, Japan, and Europe, generating milestone and royalty revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersValbonne, France
HQ citystring
Valbonne
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic therapeutics, glaucoma treatment, ocular hypertension drugs, nitric oxide donation, allergic conjunctivitis therapy
Industry2 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Nicox generates revenue primarily through licensing agreements with partners for its drug candidates. These agreements provide upfront payments, milestone payments tied to regulatory achievements (NDA submissions, approvals), and potential royalty streams from commercial sales. The company received significant milestone payments from Kowa in 2025 under licensing agreements for NCX 470.

globenewswire.com
2Royalty Revenue from Commercialized Products
TypeLicensing Royalties
Description

Nicox receives royalties from commercialized products including VYZULTA (latanoprostene bunod, marketed by Bausch + Lomb) and ZERVIATE (cetirizine ophthalmic solution, marketed by Eyevance in US and Ocumension in China). First commercial sale of ZERVIATE in China occurred in December 2024.

globenewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1NCX 470
Description

Lead product candidate - nitric oxide-donating bimatoprost eye drop for glaucoma and ocular hypertension

nicox.com
+4 more records
Core offering1 text field

Nicox develops and licenses innovative ophthalmic therapeutics based on proprietary nitric oxide (NO) donation technology. Its lead drug candidate NCX 470 is a NO-donating bimatoprost eye drop for reducing intraocular pressure in glaucoma and ocular hypertension, with NDA submissions planned in the US and China for summer 2026. The company also commercializes ZERVIATE (cetirizine ophthalmic solution) for allergic conjunctivitis and earns royalties from VYZULTA (latanoprostene bunod), marketed globally by partner Bausch + Lomb.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Up to 10mmHg intraocular pressure reduction achieved with NCX 470 in Phase 3 trials
+2 more records
Product overview1 text field

Nicox is an international ophthalmology company developing innovative therapeutics to maintain vision and improve ocular health. The company's portfolio centers on nitric oxide (NO) donation technology for eye treatments. Lead product NCX 470 (nitric oxide-donating bimatoprost) is advancing toward NDA submissions in the US and China for glaucoma treatment. Commercial products include ZERVIATE (antihistamine eye drops for allergic conjunctivitis, marketed in US and China) and VYZULTA/latanoprostene bunod (licensed to Bausch + Lomb). Pipeline includes NCX 4251 for blepharitis/dry eye and NCX 1728 for intraocular pressure reduction. The company operates through licensing partnerships globally, with Kowa (US/Japan), Ocumension (China), Bausch + Lomb (VYZULTA), Eyevance (US ZERVIATE), and Glaukos (NCX 1728) as key partners.

Product and service6 records
1NCX 470 (bimatoprost grenod)
CategoryOphthalmic Pharmaceuticals - Glaucoma
2ZERVIATE (cetirizine ophthalmic solution 0.05%)
CategoryOphthalmic Pharmaceuticals - Allergy
3VYZULTA (latanoprostene bunod ophthalmic solution 0.024%)
CategoryOphthalmic Pharmaceuticals - Glaucoma
4NCX 4251
CategoryOphthalmic Pharmaceuticals - Dry Eye / Blepharitis
5NCX 1728
CategoryOphthalmic Pharmaceuticals - Glaucoma
6Naproxcinod
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-07-17
Description

Kowa signed a key agreement worth up to €191.5 million for exclusive rights to NCX 470 in the United States and all unlicensed territories. Kowa expects to file NDA with FDA in summer 2026. The agreement includes milestone payments and royalty obligations.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-09-23
Description

Exclusive research and global licensing option agreement for NCX 1728. Glaukos has option to license worldwide rights to NCX 1728, a new class of NO-mediated IOP-lowering compound.

3Ocumension Therapeutics
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Exclusive Chinese licensee for NCX 470 and ZERVIATE. Plans to file NDA for NCX 470 in China after US submission, received positive CDE pre-submission feedback. ZERVIATE approved in China with first commercial sale in December 2024.

globenewswire.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Global licensee for VYZULTA (latanoprostene bunod). Product commercialized in 7 territories and approved in 9 additional countries. Major partner for established commercial product generating royalty revenue.

5Eyevance Pharmaceuticals
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

US commercialization partner for ZERVIATE. Expanded promotion through Hikma partnership agreement. Product launched in US market.

globenewswire.com
6Laboratorios Grin
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership for ZERVIATE commercialization in Mexico.

globenewswire.com
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensee for naproxcinod development. Obtained FDA orphan drug designation for naproxcinod in sickle cell disease treatment. Evaluating potential as COVID-19 adjuvant treatment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty ophthalmology biopharma (acquired by Astellas in 2023) focused on retinal and ophthalmic diseases. Peer to Nicox as a small-cap, late-stage ophthalmology company pursuing premium valuations based on differentiated clinical assets.

TypeBroad incumbent
Description

Global leader in eye care, including a large glaucoma pharmaceutical portfolio. Comparable to Nicox as a broad ophthalmology incumbent in the same therapeutic category, against which NCX 470 will compete commercially.

TypeDirect peer
Description

Specialty ophthalmology biopharma developing therapeutics for glaucoma and other eye diseases using drug delivery and formulation technology. Direct peer to Nicox in targeting the same ophthalmology prescribing community with pipeline-stage glaucoma products.

4Ocumension Therapeutics
TypeRegional player
Description

China-focused ophthalmology specialty company and Nicox's exclusive licensee for NCX 470 and ZERVIATE in China. Peer in business model (China ophthalmology partner-driven model) and direct commercialization counterpart in the Chinese market.

TypeDirect peer
Description

Ophthalmic medical technology and pharmaceutical company focused on novel therapies for glaucoma and other eye diseases. Partnered with Nicox on NCX 1728, and a direct peer in pursuing differentiated IOP-lowering mechanisms, including MIGS devices and pharmaceutical approaches.

6Santen Pharmaceutical
TypeBroad incumbent
Description

Established Japanese global ophthalmology company with a broad commercial portfolio including glaucoma treatments. Comparable to Nicox as a glaucoma-focused player, but at far greater scale, with existing products in major markets and overlapping R&D focus.

TypeBroad incumbent
Description

Global ophthalmology incumbent commercializing VYZULTA (Nicox's product) and a broad portfolio of eye-care products including glaucoma therapies. Direct comparator as both a partner and competitor in the glaucoma therapeutics space.

TypeDirect peer
Description

Pre-approval specialty ophthalmology company developing glaucoma therapies (Rocklatan, Rhopressa) using a differentiated mechanism. Aerie is a direct comparator to Nicox as a small-cap, partner-driven glaucoma innovator; it was acquired by Alcon in 2022, illustrating both the strategic value of glaucoma assets and the consolidation dynamic in this space.

TypeEmerging player
Description

Emerging clinical-stage ophthalmology company developing therapies for refractive and glaucoma indications. Comparable to Nicox as a smaller, pipeline-focused ophthalmology player pursuing similar patient populations in glaucoma.

TypeRegional player
Description

Japanese specialty pharmaceutical company that holds exclusive US/unspecified territory rights to NCX 470. Comparable to Nicox as a regional ophthalmology player and a direct counterparty for NCX 470's US regulatory submission and commercialization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NicOx

Ophthalmic Pharmaceuticalsnicox.com

Nicox is a France-based ophthalmology company developing nitric oxide-donating therapeutics for glaucoma and ocular diseases. It licenses its pipeline—including lead asset NCX 470—to regional pharmaceutical partners across the US, China, Japan, and Europe, generating milestone and royalty revenue.

What NicOx does

Nicox is an international ophthalmology company headquartered in Biot (Sophia Antipolis), France, developing nitric oxide (NO)-donating therapeutics to treat ocular diseases. Founded in 1996 and listed on Euronext Growth Paris under ticker ALCOX, the company employs 11-50 people and operates a wholly-owned US R&D subsidiary, Nicox Ophthalmics, Inc., in Durham, NC, focused on chemistry, manufacturing and controls and clinical development. The proprietary NO-donation platform enables novel dual-mechanism ophthalmic drugs; the lead candidate NCX 470 (NO-donating bimatoprost) demonstrated up to 10mmHg intraocular pressure reduction in Phase 3 trials with non-inferiority to latanoprost at all time points and statistical superiority at 3 of 6 time points, and is positioned for NDA submissions in the US and China in summer 2026.

The portfolio spans commercial and development assets. VYZULTA (latanoprostene bunod) is commercialized globally by partner Bausch + Lomb; ZERVIATE (cetirizine ophthalmic solution) is commercialized in the US by Eyevance and in China by Ocumension (first sale December 2024); pipeline candidates include NCX 4251 for blepharitis/dry eye, NCX 1728 (optioned to Glaukos for a new class of NO-mediated IOP-lowering agents), and naproxcinod (licensed to Fera Pharmaceuticals with FDA orphan drug designation for sickle cell disease).

Nicox operates an asset-light, partner-driven business model with no proprietary commercial infrastructure. It licenses drug candidates to regional pharmaceutical companies (Kowa for US/Japan NCX 470 under a deal worth up to €191.5M, Ocumension for China, Bausch + Lomb for VYZULTA, Eyevance for US ZERVIATE, Laboratorios Grin for Mexico, Glaukos for NCX 1728, Fera for naproxcinod), generating revenue through upfront payments, regulatory and commercial milestone payments, and royalties on partner-led sales. FY2025 revenue more than doubled to €16.8 million from €7.9 million in 2024, driven primarily by Kowa milestones; net loss narrowed sharply to €2.4 million from €22.4 million; all secured debt to Kreos Capital was fully repaid by December 31, 2025; and cash runway extends beyond 2027.

NicOx firmographics

Firmographics
Name
NicOx
Legal name
Nicox SA
Website
https://nicox.com
Company type
Public
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
Nicox is a France-based ophthalmology company developing nitric oxide-donating therapeutics for glaucoma and ocular diseases. It licenses its pipeline—including lead asset NCX 470—to regional pharmaceutical partners across the US, China, Japan, and Europe, generating milestone and royalty revenue.
Ownership category
akta.pro rank

NicOx industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Ophthalmic therapeutics
  • Glaucoma treatment
  • Ocular hypertension drugs
  • Nitric oxide donation
  • Allergic conjunctivitis therapy

Where NicOx is headquartered

Location

Headquarters

HQ city
Valbonne
HQ country
France
HQ region
Europe

Offices2 records

Markets served

NicOx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Milestone Payments: Nicox generates revenue primarily through licensing agreements with partners for its drug candidates. These agreements provide upfront payments, milestone payments tied to regulatory achievements (NDA submissions, approvals), and potential royalty streams from commercial sales. The company received significant milestone payments from Kowa in 2025 under licensing agreements for NCX 470.
  2. Royalty Revenue from Commercialized Products: Nicox receives royalties from commercialized products including VYZULTA (latanoprostene bunod, marketed by Bausch + Lomb) and ZERVIATE (cetirizine ophthalmic solution, marketed by Eyevance in US and Ocumension in China). First commercial sale of ZERVIATE in China occurred in December 2024.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels3 records

NicOx product offering

Product offering

Core offering

Nicox develops and licenses innovative ophthalmic therapeutics based on proprietary nitric oxide (NO) donation technology. Its lead drug candidate NCX 470 is a NO-donating bimatoprost eye drop for reducing intraocular pressure in glaucoma and ocular hypertension, with NDA submissions planned in the US and China for summer 2026. The company also commercializes ZERVIATE (cetirizine ophthalmic solution) for allergic conjunctivitis and earns royalties from VYZULTA (latanoprostene bunod), marketed globally by partner Bausch + Lomb.

Product overview

Nicox is an international ophthalmology company developing innovative therapeutics to maintain vision and improve ocular health. The company's portfolio centers on nitric oxide (NO) donation technology for eye treatments. Lead product NCX 470 (nitric oxide-donating bimatoprost) is advancing toward NDA submissions in the US and China for glaucoma treatment. Commercial products include ZERVIATE (antihistamine eye drops for allergic conjunctivitis, marketed in US and China) and VYZULTA/latanoprostene bunod (licensed to Bausch + Lomb). Pipeline includes NCX 4251 for blepharitis/dry eye and NCX 1728 for intraocular pressure reduction. The company operates through licensing partnerships globally, with Kowa (US/Japan), Ocumension (China), Bausch + Lomb (VYZULTA), Eyevance (US ZERVIATE), and Glaukos (NCX 1728) as key partners.

Differentiator

Problem solved

Functional benefit

Brands

  • NCX 470: Lead product candidate - nitric oxide-donating bimatoprost eye drop for glaucoma and ocular hypertension
  • ZERVIATE
  • VYZULTA
  • NCX 4251
  • NCX 1728

Products and services

  • NCX 470 (bimatoprost grenod)
  • ZERVIATE (cetirizine ophthalmic solution 0.05%)
  • VYZULTA (latanoprostene bunod ophthalmic solution 0.024%)
  • NCX 4251
  • NCX 1728
  • Naproxcinod

Quantifiable outcome

  • Up to 10mmHg intraocular pressure reduction achieved with NCX 470 in Phase 3 trials
  • +2 more outcomes

Companies that use NicOx

Customer profile

Segments2 records

Ideal customer profiles2 records

NicOx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

NicOx partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, strategic and minor.

  • KowacoreOEM/ Whitelabel/ Licensing Partner · 17 July 2025Kowa signed a key agreement worth up to €191.5 million for exclusive rights to NCX 470 in the United States and all unlicensed territories. Kowa expects to file NDA with FDA in summer 2026. The agreement includes milestone payments and royalty obligations.
  • GlaukosstrategicStrategic or Co-development Partner · 23 September 2024Exclusive research and global licensing option agreement for NCX 1728. Glaukos has option to license worldwide rights to NCX 1728, a new class of NO-mediated IOP-lowering compound.
  • Ocumension TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerExclusive Chinese licensee for NCX 470 and ZERVIATE. Plans to file NDA for NCX 470 in China after US submission, received positive CDE pre-submission feedback. ZERVIATE approved in China with first commercial sale in December 2024.
  • Bausch + LombcoreChannel Partner/ Reseller/ DistributorGlobal licensee for VYZULTA (latanoprostene bunod). Product commercialized in 7 territories and approved in 9 additional countries. Major partner for established commercial product generating royalty revenue.
  • Eyevance PharmaceuticalsminorChannel Partner/ Reseller/ DistributorUS commercialization partner for ZERVIATE. Expanded promotion through Hikma partnership agreement. Product launched in US market.
  • Laboratorios GrinminorChannel Partner/ Reseller/ DistributorPartnership for ZERVIATE commercialization in Mexico.
  • Fera PharmaceuticalsminorOEM/ Whitelabel/ Licensing PartnerLicensee for naproxcinod development. Obtained FDA orphan drug designation for naproxcinod in sickle cell disease treatment. Evaluating potential as COVID-19 adjuvant treatment.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

NicOx competitors and assessment

Company assessment

Direct peers

  • Iveric Bio (Astellas): Specialty ophthalmology biopharma (acquired by Astellas in 2023) focused on retinal and ophthalmic diseases. Peer to Nicox as a small-cap, late-stage ophthalmology company pursuing premium valuations based on differentiated clinical assets.
  • Ocular Therapeutix: Specialty ophthalmology biopharma developing therapeutics for glaucoma and other eye diseases using drug delivery and formulation technology. Direct peer to Nicox in targeting the same ophthalmology prescribing community with pipeline-stage glaucoma products.
  • Glaukos Corporation: Ophthalmic medical technology and pharmaceutical company focused on novel therapies for glaucoma and other eye diseases. Partnered with Nicox on NCX 1728, and a direct peer in pursuing differentiated IOP-lowering mechanisms, including MIGS devices and pharmaceutical approaches.
  • Aerie Pharmaceuticals: Pre-approval specialty ophthalmology company developing glaucoma therapies (Rocklatan, Rhopressa) using a differentiated mechanism. Aerie is a direct comparator to Nicox as a small-cap, partner-driven glaucoma innovator; it was acquired by Alcon in 2022, illustrating both the strategic value of glaucoma assets and the consolidation dynamic in this space.

Broad incumbents

  • Alcon: Global leader in eye care, including a large glaucoma pharmaceutical portfolio. Comparable to Nicox as a broad ophthalmology incumbent in the same therapeutic category, against which NCX 470 will compete commercially.
  • Santen Pharmaceutical: Established Japanese global ophthalmology company with a broad commercial portfolio including glaucoma treatments. Comparable to Nicox as a glaucoma-focused player, but at far greater scale, with existing products in major markets and overlapping R&D focus.
  • Bausch + Lomb: Global ophthalmology incumbent commercializing VYZULTA (Nicox's product) and a broad portfolio of eye-care products including glaucoma therapies. Direct comparator as both a partner and competitor in the glaucoma therapeutics space.

Regional players

  • Ocumension Therapeutics: China-focused ophthalmology specialty company and Nicox's exclusive licensee for NCX 470 and ZERVIATE in China. Peer in business model (China ophthalmology partner-driven model) and direct commercialization counterpart in the Chinese market.
  • Kowa Pharmaceutical: Japanese specialty pharmaceutical company that holds exclusive US/unspecified territory rights to NCX 470. Comparable to Nicox as a regional ophthalmology player and a direct counterparty for NCX 470's US regulatory submission and commercialization.

Emerging players

  • Ocuphire Pharma: Emerging clinical-stage ophthalmology company developing therapies for refractive and glaucoma indications. Comparable to Nicox as a smaller, pipeline-focused ophthalmology player pursuing similar patient populations in glaucoma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

NicOx social profiles

Digital presence

NicOx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NicOx leadership team

Management profile

Number of profiles

Profiles8 records

NicOx subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

NicOx funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NicOx M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NicOx

What does NicOx do?

Nicox develops and licenses innovative ophthalmic therapeutics based on proprietary nitric oxide (NO) donation technology. Its lead drug candidate NCX 470 is a NO-donating bimatoprost eye drop for reducing intraocular pressure in glaucoma and ocular hypertension, with NDA submissions planned in the US and China for summer 2026. The company also commercializes ZERVIATE (cetirizine ophthalmic solution) for allergic conjunctivitis and earns royalties from VYZULTA (latanoprostene bunod), marketed globally by partner Bausch + Lomb.

Is NicOx a public or private company?

NicOx is a public company. It is classified as public and is currently operating.

When was NicOx founded?

NicOx was founded in 1996. It employs 11 to 50 people.

Where is NicOx based?

NicOx is headquartered in Valbonne, France, in the Europe region.

How does NicOx make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are royalty Revenue from Commercialized Products.

Who are NicOx's main competitors?

Direct peers on record are Iveric Bio (Astellas), Ocular Therapeutix, Glaukos Corporation and Aerie Pharmaceuticals. Broad incumbents are Alcon, Santen Pharmaceutical and Bausch + Lomb. Regional players are Ocumension Therapeutics and Kowa Pharmaceutical. Ocuphire Pharma is listed as an emerging player.

Does NicOx have an API?

No public API is recorded for NicOx.

What industry is NicOx in?

NicOx's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNicox publie les résultats financiers du premier semestre 2026Nicox SA reported H1 2026 revenue of €3.5 million, up from €1.5 million in H1 2025, with operating expenses of €4.5 million versus €6.8 million. Net loss narrowed to €0.5 million from €8.9 million, and cash position stood at €6.0 million. The company expects to fund operations beyond Q1 2028.MarketScreenerNicox to present NCX 470 data at a conferenceNicox will present NCX 470 data at the 2026 American Academy of Optometry meeting in Anaheim, California. The drug candidate, designed to reduce intraocular pressure, recently completed a phase 3 clinical program across several regions worldwide.AInvestNicox's China Filing Is Real Progress — Just Don't Mistake It for a Free-Cash-Flow StoryNicox's Chinese partner Ocumension filed NCX 470 with China's drug regulator on August 10, 2026, the second major-market submission in six weeks. The filing is supported by phase 3 data showing up to 10 mm Hg IOP reduction, and milestone payments have extended the company's cash runway to beyond Q1 2028.AInvestNicox's Extended Cash Runway Is Fueled by Milestone Money, Not a BusinessNicox extended its cash runway to beyond Q1 2028, citing €8.4 million in cash and reduced fixed costs. The extension was funded by a €3 million milestone from Kowa and a shareholder loan from Vester Finance, with dilution as the cost. The next key event is the FDA decision on NCX 470 on April 30, 2027.FinancialContent Business PageNicox Announces April 2027 PDUFA Date for NCX 470 in GlaucomaNicox SA announced on August 27, 2026 that the FDA has accepted its New Drug Application for NCX 470, a nitric oxide-donating bimatoprost eye drop for glaucoma, and set April 30, 2027 as the PDUFA review response date. The NDA was filed by U.S. licensee Kowa on June 30, 2026, based on positive Mont Blanc and Denali Phase 3 trials showing up to 10mmHg IOP reduction. Nicox expects a U.S. launch in H2 2027, with a milestone payment and royalties on sales.MorningstarKowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular HypertensionKowa Pharmaceuticals America announced the FDA accepted its NDA for K-911, an investigational once-daily bimatoprost eye drop for open-angle glaucoma or ocular hypertension. The FDA assigned a PDUFA target action date of April 30, 2027, and Kowa expects a U.S. commercial launch in the second half of 2027, subject to approval.Ophthalmology TimesNicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertensionNicox has completed the Denali phase 3 trial of NCX 470, a treatment for open-angle glaucoma or ocular hypertension, with all 696 patients successfully finishing their treatment and follow-ups. The company anticipates announcing topline results in mid-August to mid-September 2025, with plans to submit a New Drug Application to the US FDA in the first half of 2026. This trial is crucial for NCX 470's regulatory pathway in the US and China.Ophthalmology TimesMont Blanc Phase 3 glaucoma trial for NCX 470 achieves primary objectiveNicox SA announced that its Phase 3 clinical trial, Mont Blanc, for NCX 470 achieved its primary objective of non-inferiority in lowering intraocular pressure compared to latanoprost. The trial showed that NCX 470 resulted in an intraocular pressure reduction of 8.0 to 9.7 mm Hg versus 7.1 to 9.4 mm Hg for latanoprost, with results being statistically significant at 4 of 6 timepoints. The company plans to continue analyzing the Mont Blanc data to further define NCX 470's profile and potential effects on retinal cell protection.Applied Clinical TrialsNCX 470 Meets Phase III Goal in Glaucoma With Strong Intraocular Pressure ReductionsNicox has reported the successful results of its Phase III Denali trial for NCX 470, a new eye drop treatment for glaucoma, demonstrating non-inferiority to standard care in lowering intraocular pressure. The trial included 696 patients across 90 sites in the US and China, confirming positive results consistent with the earlier Mont Blanc trial, thereby supporting NCX 470's potential as a significant treatment option. The study's successful outcomes could facilitate regulatory submissions for the new treatment.Ophthalmology TimesNCX 470 advances toward US, China NDA submissions for NCX 470Nicox has acquired and analyzed all necessary data to support New Drug Application (NDA) submissions for its glaucoma drug candidate NCX 470 in the US and China. The company plans to submit the NDA to the FDA in the first half of 2026, with Kowa preparing for the process as the exclusive licensing partner for the US market. Following this submission, Nicox expects to file the NDA in China shortly thereafter.